生脉注射液联合刺五加注射液治疗冠心病心绞痛临床疗效分析  

Efficacy of Shengmai injection combined with Ciwujia injection in the treatment of coronary heart disease angina pectoris

在线阅读下载全文

作  者:韩杰[1] 赵香玉[1] 麻凤清[1] 

机构地区:[1]佳木斯大学校医院,黑龙江佳木斯154007

出  处:《黑龙江医药科学》2004年第6期24-25,共2页Heilongjiang Medicine and Pharmacy

摘  要:目的 :联合应用生脉注射液和刺五加注射液治疗冠心病心绞痛 ,观察疗效及不良反应。方法 :对 110例冠心病心绞痛病人随机分成两组 ,对照组 (A组 )给予抗心绞痛常规治疗 ,治疗组 (B组 )在常规治疗的基础上给予生脉注射液 30 ml+5 %GS2 5 0 ml和刺五加注射液 4 0 ml+5 % GS2 5 0 ml分步静滴 ,每日 1次 ,疗程 2周 ,观察两组患者用药前后心绞痛症状、心电图、血流变改变情况及不良反应。结果 :A组与 B组在改善心绞痛疗效总有效率分别为 76 .4 % ,94 .5 % (P <0 .0 1) ,心电图疗效分别为 5 6 .4 % ,81.8% (P <0 .0 5 ) ,对血液流变学的影响 B组优于 A组 (P <0 .0 1) ,未见副反应。结论 :生脉注射液联合刺五加注射液治疗冠心病心绞痛疗效显著 。Objective: To investigate the effect of Shengmai injection combined with Ciwujia injection in the treatment of coronary heart disease (CHD) angina pectoris. Methods: In our study, 110 patients with angina pectoris were randomly divided into two groups. The control group (group A) was given the routine therapy of anti-angina pectoris. the treatment group (group B), on the basis of normal treatment, was injected with Shengmai 30ml + 5 % GS250ml 1/d and Ciwujia 40ml + 5 % GS250ml one time a day for two weeks. The symptom of angina pectoris, the changes in ECG and BF and the side effects were observed before and after treatment. Results: Angina pectoris was relieved in both groups, but the total effective rate was 76.4% in group A, and 94.5% in group B, with a significant difference between the two groups (P<0.01) .The depressed ST-T segment of ECG was relieved in the two groups. The BF change in group B was significantly increased than that in group A (P<0.01). No side effects were observed. Conclusion: Shengmai injection combinated with Ciwujia injection is effective in the treatment of CHD angina pectoris. No adverse reaction was found.

关 键 词:冠心痛心绞痛 生脉注射液 刺五加注射液 

分 类 号:R541.4[医药卫生—心血管疾病]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象